PMID- 33467441
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Electronic)
IS  - 2227-9032 (Linking)
VI  - 9
IP  - 1
DP  - 2021 Jan 15
TI  - May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical 
      Experience in a Patient with Chronic Lymphocytic Leukemia.
LID - 10.3390/healthcare9010078 [doi]
LID - 78
AB  - COVID-19 is affecting many countries all around the world. Unfortunately, no 
      treatment has already been approved for the management of patients infected by 
      SARS-CoV-2. It seems that SARS-CoV-2 can induce the activation of an exaggerated 
      immune response against itself according to different mechanisms that are not 
      really well known. Inflammatory interleukins, such as IL-6 among others, play a 
      central role in this uncontrolled immune response. There is a strong rational 
      under ibrutinib use in in the treatment of immune-based diseases, such a as GVHD 
      or RA. Ibrutinib achieves a reduction in the production of TNFalpha, IL1, IL-6 and 
      Monocyte chemo-attractant protein-1 (MCP-1) by neutrophils and macrophages, that 
      are key players in keeping the inflammatory process. We present our clinical 
      experience about ibrutinib use in ARDS secondary to SARS-CoV-2 in a patient with 
      chronic lymphocytic leukemia (CLL).
FAU - Molina-Cerrillo, Javier
AU  - Molina-Cerrillo J
AUID- ORCID: 0000-0003-4616-0598
AD  - Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, 
      Spain.
AD  - The Ramon y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, 
      Spain.
AD  - Medical School, Alcala University, 28805 Madrid, Spain.
FAU - Marquet-Palomanes, Juan
AU  - Marquet-Palomanes J
AD  - The Ramon y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, 
      Spain.
AD  - Hematology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain.
FAU - Alonso-Gordoa, Teresa
AU  - Alonso-Gordoa T
AUID- ORCID: 0000-0002-8966-7236
AD  - Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, 
      Spain.
AD  - The Ramon y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, 
      Spain.
AD  - Medical School, Alcala University, 28805 Madrid, Spain.
FAU - Lopez-Jimenez, Javier
AU  - Lopez-Jimenez J
AD  - The Ramon y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, 
      Spain.
AD  - Medical School, Alcala University, 28805 Madrid, Spain.
AD  - Hematology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain.
FAU - Grande, Enrique
AU  - Grande E
AD  - MD Anderson Cancer Center, 28033 Madrid, Spain.
LA  - eng
PT  - Case Reports
DEP - 20210115
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7830068
OTO - NOTNLM
OT  - BTK
OT  - COVID19
OT  - SARS-CoV-2
OT  - ibrutinib
COIS- Juan Marquet: Janssen, Roche, Gilead (SAB), Abbvie (C/A). Enrique Grande: Pfizer, 
      Bristol-Myers Squibb, Ipsen, Roche, Eisai, Eusa Pharma, MerckSharp&Dohme, 
      Sanofi-Genzyme, Adacap, Novartis, PierreFabre, Lexicon, Celgene (C/A, SAB), 
      Pfizer, AstraZeneca, MTEM/Threshold, Roche, Ipsen, Lexicon (RF). The rest of 
      authors declares no conflict of interest. (C/A): Consulting/Advisory 
      relationship; (RF) Research Funding; (SAB) Scientific Advisory Board.
EDAT- 2021/01/21 06:00
MHDA- 2021/01/21 06:01
PMCR- 2021/01/15
CRDT- 2021/01/20 01:09
PHST- 2020/12/08 00:00 [received]
PHST- 2021/01/13 00:00 [revised]
PHST- 2021/01/14 00:00 [accepted]
PHST- 2021/01/20 01:09 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/21 06:01 [medline]
PHST- 2021/01/15 00:00 [pmc-release]
AID - healthcare9010078 [pii]
AID - healthcare-09-00078 [pii]
AID - 10.3390/healthcare9010078 [doi]
PST - epublish
SO  - Healthcare (Basel). 2021 Jan 15;9(1):78. doi: 10.3390/healthcare9010078.